Strata Skin Sciences (SSKN) Notified of Nasdaq Equity Non-Compliance

Strata Skin Sciences, Inc. disclosed that on August 19, 2025 Nasdaq notified the company it is not in compliance with the Nasdaq Capital Market minimum stockholders' equity requirement of $2,500,000.

Rhea-AI Filing Summary

Strata Skin Sciences, Inc. disclosed that on August 19, 2025 Nasdaq notified the company it is not in compliance with the Nasdaq Capital Market minimum stockholders' equity requirement of $2,500,000. The company's Quarterly Report for the quarter ended June 30, 2025 reported stockholders' equity below that threshold and the company does not meet alternative Nasdaq standards related to market value of listed securities or net income from continuing operations.

The Notice does not immediately affect the listing and the common stock continues trading under the symbol SSKN. Nasdaq gave Strata 45 calendar days, until October 3, 2025, to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days from the Notice date to evidence compliance. The company is evaluating options and plans to timely submit a plan, but stated there is no assurance the plan will be accepted or that compliance will be achieved.

Positive

• Common stock remains listed and trading on The Nasdaq Capital Market under the symbol SSKN despite the Notice
• Nasdaq provided a clear timeline (45 days to submit a plan, potential extension up to 180 days) allowing the company time to pursue remediation

Negative

• Company is not compliant with Nasdaq's minimum stockholders' equity requirement of $2,500,000
• Company does not meet alternative Nasdaq standards related to market value of listed securities or net income from continuing operations, limiting cure options
• No assurance the company's cure plan will be accepted, and failure could result in delisting proceedings

Insights

Securities Analyst

TL;DR: Nasdaq issued a non-compliance notice for stockholders' equity; company has limited time to submit a cure plan.

Nasdaq's determination is strictly tied to the regulatory threshold of $2.5 million in stockholders' equity. The company disclosed it also fails to meet alternative compliance tests related to market value and net income, which narrows remedy options to measures that directly bolster shareholders' equity or secure an approved cure plan. The 45-day submission window followed by a potential 180-day cure period creates a defined timeline for remediation; failure could lead to delisting proceedings, though appeal rights and a hearing process provide procedural protections. This is a governance and capital-structure issue rather than an operational earnings disclosure.

Corporate Governance Expert

TL;DR: The filing signals a material listing risk tied to balance-sheet metrics, requiring capital or structural remedies.

The company's explicit statement that it does not satisfy Nasdaq's equity threshold or alternative standards means typical remedies include equity financings, reverse splits tied to market value requirements, or securing strategic transactions to restore equity. The filing appropriately outlines procedural timelines and the possibility of appeal, but provides no details on which remedial actions management is considering. Investors should view this as a significant compliance event that could affect liquidity and listing status if not resolved.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Strata Skin Sciences (SSKN) disclose about Nasdaq compliance?

The company disclosed Nasdaq found it was not in compliance with the minimum stockholders' equity requirement of $2,500,000 and does not meet alternative market value or net income standards.

Will SSKN’s stock be suspended or delisted immediately?

No. The Notice has no immediate effect and the common stock continues trading under SSKN; Nasdaq provided time to submit a compliance plan.

What timeline did Nasdaq give SSKN to regain compliance?

Nasdaq gave the company 45 calendar days (until October 3, 2025) to submit a plan; if accepted, Nasdaq may grant up to 180 calendar days from the Notice to evidence compliance.

What remedies did the filing say the company is considering?

The filing states the company is evaluating various courses of action and plans to submit a plan to regain compliance but does not specify which actions.

Can the company appeal a delisting determination?

Yes. The filing notes Nasdaq rules permit the company to appeal any delist determination and that requesting a hearing would stay suspension or delisting pending review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/22/2025 - 04:30 PM Learn about SEC filing dates

false0001051514NASDAQ00010515142025-08-192025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

STRATA SKIN SCIENCES, INC.

(Exact name of registrant as specified in its Charter)

Delaware	000-51481	13-3986004
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5 Walnut Grove Drive, Suite 140

Horsham, Pennsylvania 19044

(Address of principal executive offices) (Zip Code)

215-619-3200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

			Trading		Name of each exchange
	Title of each class		Symbol(s)		on which registered
	Common Stock, $0,001 par value per share		SSKN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 19, 2025, Strata Skin Sciences, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders’ equity below the Stockholders’ Equity Requirement for continued listing, and as of the date of this report, the Company does not meet any alternative Nasdaq compliance standards relating to the market value of listed securities or net income from continuing operations.

The Notice has no immediate effect on the listing of the Company’s common stock and the Company’s common stock continues to trade on The Nasdaq Capital Market under the symbol “SSKN,” subject to the Company’s compliance with the other continued listing requirements.

Pursuant to the Notice, Nasdaq has given the Company 45 calendar days, or until October 3, 2025, to submit to Nasdaq a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice to evidence compliance.

The Company is currently evaluating various courses of action to regain compliance and plans to timely submit its plan to Nasdaq to regain compliance with the Stockholders’ Equity Requirement. There can be no assurance that the Company’s plan will be accepted or that if it is, the Company will be able to regain compliance. If the Company’s plan to regain compliance is not accepted, or if it is and the Company does not regain compliance within 180 days from the date of Nasdaq’s letter, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company’s common stock will become subject to delisting. In such event, Nasdaq rules permit the Company to appeal any delist determination. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

Forward-Looking Statements

Certain statements contained in this Current Report on Form 8-K are not historical facts and are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. This information includes, without limitation, statements concerning the Company’s intention or ability to regain compliance with the applicable Nasdaq listing requirements, the Company’s intention to appeal the Nasdaq staff’s determination, the Company’s expectation that a request for a Panel hearing will stay the suspension of the Company’s securities pending the Panel’s decision, the timing and nature of any hearing before the Panel, the outcome of the Panel’s review of any Company appeal of the Nasdaq staff’s determination, and any courses of action to regain compliance with the applicable Nasdaq listing requirements. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of its annual report on Form 10-K for the fiscal year ended December 31, 2024, and any risks that may be contained in any subsequent filings that the Company makes with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		STRATA SKIN SCIENCES, INC.
Dated: August 22, 2025	By:	/s/ John Gillings
		John Gillings
		Chief Accounting Officer